International Journal of Health and Pharmaceutical (IJHP)
Cure8 research brief
Why This Matters
Arthritis is a common and meaningful extraintestinal problem for people with IBD; understanding diagnosis and treatment options can help patients and clinicians seek appropriate multidisciplinary care.
Who Should Pay Attention
Patients with IBD experiencing joint symptoms, gastroenterologists, rheumatologists, and researchers interested in gut–joint mechanisms
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article (abstract) describes IBD-associated arthritis as including peripheral (often non-erosive, sometimes tied to bowel activity) and axial forms (sacroiliitis/ankylosing spondylitis) that can progress independently of gut inflammation.
The review highlights proposed mechanisms linking gut and joint disease (intestinal immune extension, gut microbiota dysregulation with Th17 activation, and genetic risk factors such as HLA-B27 and NOD2/CARD15).
For treatment, the abstract notes anti-TNF agents are recommended first-line for active joint disease, and names other targeted options discussed in the review (JAK inhibitors, ustekinumab, vedolizumab). It emphasizes multidisciplinary care between gastroenterology and rheumatology.
Keep In Mind
This record is based on the article abstract/summary from the journal; it summarizes review-level evidence rather than new clinical trial data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational Journal of Health and Pharmaceutical (IJHP)
PublisherInternational Journal of Educational Research & Social Sciences (IJERSC)
AuthorsIqbal Habibie, Najirman, Eka Kurniawan
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 30, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Current and novel biomarkers for predicting and assessing therapeutic response in inflammatory bowel disease: a systematic review.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...